Aethlon Medical is closely monitoring the Bird Flu situation and stands ready to work alongside hospitals, health agencies and the FDA if existing therapies prove inadequate.
The Aethlon Hemopurifier
The Aethlon Hemopurifier® is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a “Breakthrough Device” for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and life-threatening viruses that are not addressed with approved therapies.
The Hemopurifier®’s Unique Mechanism of Action Captures Virus and Exosomes from a Patient’s Blood via an Extracorporeal Circuit
![Captures enveloped viral pathogens and exosomes in circulating blood. Hollow-fiber plasma separator filled with proprietary “affinity resin” [Figures B, C]. Size restriction: < 200nm diameter to access “affinity resin” [Figure C]. Affinity resin captures mannosylated nano particles (e.g., enveloped virus, exosomes) [Figure D]. Compatible with existing dialysis or CRRT infrastructure [Figure A].](https://d1io3yog0oux5.cloudfront.net/_d2c0596dbd6d89b64b38c83736c0d77e/aethlonmedical/files/pages/the-hemopurifier/Hemopurifier.png)
- Safely administered in 165 Hemopurifier sessions in 39 patients1
- Proprietary, patented technology
- Demonstrated clearance of life-threatening viruses
- Designed to clear tumor-derived EVs, and their associated cargo (Oncology)
1Aethlon Clinical Database
Therapeutic Potential
- Life-threatening viral infections, such as Ebola, H5N1, etc.
- Cancer